↑ 薬物リストへ　← 戻る

Sifalimumab 200 mg    (DrugBank: Sifalimumab)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
49全身性エリテマトーデス1

49. 全身性エリテマトーデス　［臨床試験数：827，薬物数：638（DrugBank：168），標的遺伝子数：108，標的パスウェイ数：191］
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 827 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01283139
(ClinicalTrials.gov)		March 31, 201120/1/2011A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus ErythematosusA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus ErythematosusSystemic Lupus ErythematosusBiological: Sifalimumab 200 mg;Biological: Sifalimumab 600 mg;Biological: Sifalimumab 1,200 mg;Other: PlaceboMedImmune LLCNULLCompleted18 Years75 YearsAll834Phase 2United States;Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Jamaica;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom